Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- presencia de factores de riesgo
- más de 6 semanas de duración
- dolor en las articulaciones
- inflamación de las articulaciones
- fiebre
Otros factores de diagnóstico
- rigidez matinal
- cojera
- movimiento limitado
- erupción
- entesitis
- discrepancia en la longitud de las extremidades
- uveítis
- nódulos reumatoides
Factores de riesgo
- sexo femenino
- polimorfismo del HLA
- edad menor a 6 años
- antecedentes familiares de autoinmunidad
- la exposición a antibióticos durante la infancia
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- hemograma completo (HC)
- velocidad de sedimentación globular
- proteína C-reactiva
- anticuerpos antinucleares (ANA)
- factor reumatoide (FR)
Pruebas diagnósticas que deben considerarse
- anticuerpo antipéptido cíclico citrulinado
- prueba de clamidia
- niveles de ferritina
- ecografía de las articulaciones afectadas
- resonancia magnética (IRM)
Algoritmo de tratamiento
Colaboradores
Autores
Consultant Paediatric Rheumatologist
Department of Paediatric Rheumatology
Bristol Royal Hospital for Children
Bristol
UK
Divulgaciones
JC declares that she has no competing interests.
Consultant Rheumatologist
ONE Centre for Rheumatology and Genetics
Vadodara
Gujarat
India
Divulgaciones
RS declares that he has no competing interests.
Dr Jacqui Clinch and Dr Ripal Shah would like to gratefully acknowledge Dr Eve Bassett, Dr Sheila Angeles-Han, and Dr Sampath Prahalad, the previous contributors to this monograph. EB declares that she has no competing interests. SAH and SP are authors of a number of references cited in this monograph. SP is the recipient of research funding from the National Institute of Health and Arthritis Foundation.
Revisores por pares
Clinical Director
Division of Pediatric Rheumatology
Children's Hospital of Pittsburgh
Pittsburgh
PA
Divulgaciones
PR declares that he has no competing interests.
Director
Division of Rheumatology
Professor of Pediatrics
Department of Pediatrics
Medical University of South Carolina
Charleston
SC
Divulgaciones
MP is an author of a number of references cited in this monograph. He is a consultant to Pfizer Pharmaceuticals as the chairman of the Expert Advisory Panel to review toxicity of celecoxib. He has been a visiting professor from the American College of Rheumatology, and from the American Academy of Pediatrics.
Professor of Paediatric Rheumatology
University College London
London
UK
Divulgaciones
Not disclosed.
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad